Lupin, India’s fourth-largest drug-maker by sales is planning to launch three-four new generic drugs in its key US market by end of FY13. So far, the company has launched six products in this fiscal in the United States, which generates about 42% of its total formulation sales.
The drug-maker earlier reported a forecast-beating 42.6% rise in quarterly net profit to Rs 335 crore.
The company, on consolidated basis, reported 42.61% rise in its net profit at Rs 335.23 crore for the quarter ended December 31, 2012 as compared to Rs 235.06 crore for the same quarter in the previous year. Total income of the company increased by 38.71% at Rs 2527.57 crore for quarter under review as compared to Rs 1822.24 crore for the quarter ended December 31, 2011.
